Editorial: trends in paediatric inflammatory bowel disease attributable direct costs-authors' reply

被引：0
|
作者：
El-Matary, Wael [1 ,2 ]
Nugent, Zoann [2 ,3 ]
Witt, Julia [4 ]
Bernstein, Charles N. [2 ,3 ]
机构：
[1] Univ Manitoba, Dept Pediat, Winnipeg, MB, Canada
[2] Univ Manitoba, IBD Clin & Res Ctr, Winnipeg, MB, Canada
[3] Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada
[4] Univ Manitoba, Dept Econ, Winnipeg, MB, Canada
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2021年 / 53卷 / 11期
关键词：
CROHNS-DISEASE; CHILDREN; TNF;
D O I：
10.1111/apt.16376
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
LINKED CONTENT This article is linked to El-Matary et al and Vernon-Roberts & Day papers. To view these articles, visit and
引用
收藏
页码：1234 / 1235
页数：2
相关论文
共 50 条
  • [1] Editorial: trends in paediatric inflammatory bowel disease attributable direct costs
    Vernon-Roberts, Angharad
    Day, Andrew S.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 53 (11) : 1232 - 1233
  • [2] Trends in paediatric inflammatory bowel disease-attributable direct costs: a population-based analysis
    El-Matary, Wael
    Nugent, Zoann
    Witt, Julia
    Bernstein, Charles N.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 53 (11) : 1201 - 1208
  • [3] The changing epidemiology of paediatric inflammatory bowel disease: authors' reply
    Chouraki, V.
    Turck, D.
    Colombel, J. -F.
    Gower-Rousseau, C.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (12) : 1381 - 1382
  • [4] Editorial: anxiety and depression in inflammatory bowel disease - authors' reply
    Stapersma, Luuk
    van den Brink, Gertrude
    Szigethy, Eva M.
    Escher, Johanna C.
    Utens, Elisabeth M. W. J.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (06) : 687 - 688
  • [5] Trends in Pediatric Inflammatory Bowel Disease-attributable direct costs: A Canadian population-based analysis
    El-Matary, W.
    Nugent, Z.
    Witt, J.
    Bernstein, C.
    [J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S559 - S559
  • [6] Editorial: treating strictures in inflammatory bowel disease-authors' reply
    Rieder, Florian
    Feagan, Brian G.
    Jairath, Vipul
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (11-12) : 1313 - 1314
  • [7] Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease: authors' reply
    Jakobsen, C.
    Bartek, J., Jr.
    Wewer, V.
    Vind, I.
    Munkholm, P.
    Groen, R.
    Paerregaard, A.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (03) : 392 - 393
  • [8] Letter: screening for adrenal suppression in paediatric inflammatory bowel disease - authors' reply
    Philpott, Hamish
    Dougherty, Michael K.
    Dellon, Evan S.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (08) : 885 - 886
  • [9] Editorial: direct costs are only the tip of the iceberg in inflammatory bowel disease
    Vasudevan, Abhinav
    van Langenberg, Daniel R.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (05) : 879 - 880
  • [10] Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease-authors' reply
    Fairbrass, Keeley M.
    Hamlin, P. John
    Gracie, David J.
    Ford, Alexander C.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (08) : 1302 - 1303
12345